the company has one huge drug called copaxone for multiple sclerosis, $3.8 billion in sales last yeared for 19% of the company's total revenues. likely to face tough competition, a new ms drug, i profiled last week. it was two weeks ago. the stock is up very, very big. but the big worry here is simply that copaxone's patent only lasts through 2015, two years from now. and some terms start to expire next year. in other words, teva is about to fall off a gigantic patent cliff of its own! as other generic drug makers swoop in to copy copaxone and crush the price of a drug that now really represents about -- geez, represents about a fifth of the company sales. teva is now on the other side of the patent expiration gate and i'm sure they don't like it one bit. talk about poetic justice. then the generic side of the business, accounts for half the sales, the generic drug business not what it used to be. over the last five years, the big phrma companies have been going over what everyone calls a gigantic patent cliff as tens upon tens of billions of dollars worth of branded drugs, including